NCT07652983Not yet recruiting
TTE Study of QL1706 in Recurrent/Metastatic Cervical Cancer
Real-World Effectiveness and Safety of Iparomlimab and Tuvonralimab in Recurrent or Metastatic Cervical Cancer: A Target Trial Emulation Study
Source: ClinicalTrials.gov · Last updated 17 Jun 2026
Brief summary (registry, in English)
The goal of this observational study is to evaluate the effectiveness and safety of Iparomlimab and Tuvonralimab (QL1706)-based therapy in patients with recurrent or metastatic cervical cancer who have experienced disease progression after platinum-based treatment. The main questions it aims to answer are: * Does QL1706-based therapy improve clinical outcomes compared with investigator-selected chemotherapy in patients with recurrent or metastatic cervical cancer? * Does the addition of bevacizumab further improve treatment effectiveness? * Which patient subgroups are most likely to benefit from QL1706-based therapy? Participants receiving QL1706-based therapy or investigator-selected chemotherapy as part of routine clinical practice will be followed through real-world clinical data collection. Using a target trial emulation framework, the study will compare treatment effectiveness and safety between groups. Clinical characteristics, treatment outcomes, and adverse events will be collected for analysis. In addition, artificial intelligence-based models and multi-omics analyses will be used to identify predictive biomarkers and explore potential mechanisms of treatment response and resistance.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 280 (estimated)
- First submitted
- 11 Jun 2026
- Start date
- Jun 2026
- Primary completion date
- Dec 2028
- Lead sponsor
- Qilu Hospital of Shandong University
- Diseases
- Cervical cancer
- NCT number
- NCT07652983
What you commit to
- Study type: Observational
- Planned participants: 280
- From Jun 2026 to the primary completion date, Dec 2028
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Histological subtypes including sarcoma, small-cell carcinoma with neuroendocrine differentiation, or other non-epithelial malignancies.
- History of severe hypersensitivity reaction (Grade ≥3) to Iparomlimab and Tuvonralimab (QL1706) and/or any of its excipients.
- Known additional malignancy that has progressed or required active treatment within the past 3 years.
- Active autoimmune disease requiring systemic treatment within the past 2 years (e.g., disease-modifying agents, corticosteroids, or immunosuppressive therapy); history of non-infectious pneumonitis requiring steroid treatment, or current pneumonitis.
- Active infection requiring systemic therapy.
Lab values
- Any other medical condition, laboratory abnormality, or circumstance that, in the investigator's judgment, would make the participant unsuitable for participation in this study.
Who the study is looking for
- Participants voluntarily agree to participate in the study and provide written informed consent.
- Age ≥18 years at the time of signing the informed consent form.
- Histologically confirmed recurrent or metastatic cervical cancer (FIGO 2018 stage IVB), including squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma.
- Disease progression or treatment failure following prior platinum-based chemotherapy.
- At least one measurable target lesion according to RECIST version 1.1, as assessed by CT or MRI.
- Estimated life expectancy of at least 3 months.
- Considered suitable by the investigator for antitumor treatment with Iparomlimab and Tuvonralimab (QL1706), either as monotherapy or in combination with other therapies, and with a planned treatment regimen including QL1706.
Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.